Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Duxin Sun

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6406-2126; OpenAlex author ID A5069778809; NIH RePORTER profile ID 7946935. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 8)
Trials
0
Grants
1
Labs led
1
Collaborators
20
Papers, trials and grants by year

2011: 1 paper, 1 grant · 2012: 1 paper · 2013: none · 2014: 2 papers · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 12

  1. Dual targeting of PI3Kγ and STING overcomes regulatory B cell- and myeloid cell-driven immune suppression in pancreatic cancer. Last author DOI 10.1038/s43018-026-01158-7↗
  2. Copper-KRAS-COX2 Axis: A Therapeutic Vulnerability in Pancreatic Cancer. Co-author DOI 10.1021/acs.jmedchem.4c03159↗
  3. Dual Targeting of STING and PI3Kγ Eliminates Regulatory B Cells to Overcome STING Resistance for Pancreatic Cancer Immunotherapy Last author DOI 10.1101/2024.02.14.580378↗
  4. Design and Synthesis of Orally Active Quinolyl Pyrazinamides as Sigma 2 Receptor Ligands for the Treatment of Pancreatic Cancer. Co-author DOI 10.1021/acs.jmedchem.2c01769↗
  5. Multiparameter Optimization of Oxidative Phosphorylation Inhibitors for the Treatment of Pancreatic Cancer. Co-author DOI 10.1021/acs.jmedchem.1c01934↗
  6. [Preoperative C-reactive protein/albumin ratio predicts the prognosis of patients with resectable pancreatic cancer]. Last author DOI 10.3760/cma.j.issn.0529-5815.2018.09.013↗
  7. Over-Expression of Alpha-Enolase as a Prognostic Biomarker in Patients with Pancreatic Cancer. Last author DOI 10.7150/ijms.18736↗
  8. CPA4 is a promising diagnostic serum biomarker for pancreatic cancer. Last author PMID 27073726↗
  9. Structure-activity relationship (SAR) of withanolides to inhibit Hsp90 for its activity in pancreatic cancer cells. Last author DOI 10.1007/s10637-013-9987-y↗
  10. A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo. Co-author DOI 10.1158/1535-7163.mct-12-0767↗
  11. Sulforaphane inhibits pancreatic cancer through disrupting Hsp90-p50(Cdc37) complex and direct interactions with amino acids residues of Hsp90. Last author DOI 10.1016/j.jnutbio.2011.11.004↗
  12. Sulforaphane potentiates the efficacy of 17-allylamino 17-demethoxygeldanamycin against pancreatic cancer through enhanced abrogation of Hsp90 chaperone functi… Last author DOI 10.1080/01635581.2011.596645↗

Grants 1

  1. New molecular target and its inhibitors for use against pancreatic cancer R21CA143474↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Joyeeta Roy · 3 shared papers, 2022–2025 · strength 0.64
  2. Yibin Xu · 3 shared papers, 2022–2025 · strength 0.64
  3. Nouri Neamati · 3 shared papers, 2022–2025 · strength 0.64
  4. Lawrence H. Fong · 1 shared paper, 2026 · strength 0.22
  5. Christopher I. Li · 1 shared paper, 2026 · strength 0.22
  6. Vaibhav Sahai · 1 shared paper, 2026 · strength 0.22
  7. Deepak Nagrath · 1 shared paper, 2026 · strength 0.22
  8. Chengyi Li · 1 shared paper, 2024 · strength 0.18
  9. Ding Xue · 1 shared paper, 2022 · strength 0.17
  10. Lichao Sun · 2 shared papers, 2016–2017 · strength 0.14
  11. Yuliang Ran · 2 shared papers, 2016–2017 · strength 0.14
  12. B Y Luo · 1 shared paper, 2018 · strength 0.10
  13. Mancang Gu · 1 shared paper, 2014 · strength 0.05
  14. Yanyan Li · 1 shared paper, 2011 · strength 0.04
  15. Zaneta Nikolovska-Coleska · 1 shared paper, 2014 · strength 0.04
  16. Fardokht A. Abulwerdi · 1 shared paper, 2014 · strength 0.04
  17. Amro Aboukameel · 1 shared paper, 2014 · strength 0.04
  18. Ramzi M. Mohammad · 1 shared paper, 2014 · strength 0.04
  19. Asfar Sohail Azmi · 1 shared paper, 2014 · strength 0.04
  20. Yanyan Li · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.